Healthcare question

Should fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) staging exams vs. no PET staging exams be used for patients with clinical stage 1 breast cancer without symptoms suggestive of metastases?

Recommendation

For breast cancer patients without symptoms suggestive of metastases at clinical stage 1, the ECIBC's Guidelines Development Group (GDG) recommends against using positron emission tomography-computed tomography (PET-CT).

Recommendation strength ­

  Strong recommendation against the intervention

  Very low certainty of the evidence

Subgroup considerations

For triple negative tumours and HER2 positive evidence suggests that there is no additional benefit because of no increased risks from metastases.

Research priorities

The GDG suggests research to clarify the clinical significance of true positives (for all stages).

Supporting documents